Risk assessment and management of anthracycline and HER2 receptor inhibitor-induced cardiomyopathy

Jahangir, Eiman, Shah, Sangeeta, Shum, Kelly, Baxter, Caitlin, Fitzpatrick, Jill D., Cole, John, Gilliland, Yvonne and Polin, Nichole M. (2015) Risk assessment and management of anthracycline and HER2 receptor inhibitor-induced cardiomyopathy. Southern Medical Journal, 108 2: 71-78. doi:10.14423/SMJ.0000000000000232

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Jahangir, Eiman
Shah, Sangeeta
Shum, Kelly
Baxter, Caitlin
Fitzpatrick, Jill D.
Cole, John
Gilliland, Yvonne
Polin, Nichole M.
Title Risk assessment and management of anthracycline and HER2 receptor inhibitor-induced cardiomyopathy
Journal name Southern Medical Journal   Check publisher's open access policy
ISSN 0038-4348
1541-8243
Publication date 2015-02-01
Sub-type Article (original research)
DOI 10.14423/SMJ.0000000000000232
Open Access Status Not yet assessed
Volume 108
Issue 2
Start page 71
End page 78
Total pages 8
Place of publication Lippincott Williams & Wilkins
Publisher Philadelphia, PA, United States
Collection year 2016
Language eng
Abstract With the advent and increased use of chemotherapeutic agents and radiation therapy, cancer survival rates have increased. With increased survival, both acute and chronic cardiotoxic adverse effects have emerged. The growing need for managing the treatment of individuals with chemotherapy-induced cardiotoxicity has led to the formation of cardio-oncology programs throughout the United States. These programs concentrate on many aspects of cardiac disease in the oncology patient. Of these, the cardiotoxic effects (particularly cardiomyopathy) of anthracyclines and HER2 receptor inhibitors are a large focus of cardio-oncology practice. Despite the increasing availability of these programs, no consensus guidelines have been established to provide a framework for treating these patients. This review describes the initial evaluation, risk assessment, and management of individuals receiving anthracycline and HER2 receptor inhibitor therapy for cardiomyopathy. These recommendations are supported by the current literature in this field.
Keyword Cardiomyopathy
Cardiotoxicity
Chemotherapy
Oncology
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2016 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Sun, 19 Apr 2015, 11:00:44 EST by System User on behalf of Scholarly Communication and Digitisation Service